4basebio AG announces the allotment ratio and the final number of shares for the announced share buyback program.
Heidelberg, Germany, and Cambridge, UK, 21 February 2020 – 4basebio AG (formerly Expedeon AG) (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) today announces the allotment ratio and the final number of shares for the announced share buyback program. With an allotment quota of rounded 93.66% of the accepting shareholders, the Company will buy back a total of 5,230,667 shares, which represents approximately 10.00% of the share capital. The settlement of the offer is expected to take place on 24 February 2020.
As part of the share buyback offer 5,584,558 shares within the price range of EUR 1.60 to EUR 1.85 have been tendered to 4basebio AG by the end of the acceptance period on 10 February 2020. In accordance with the offer and the volume increase decided by the Management Board on 10 February 2020, the offer of 4basebio AG related to a buyback of up to 5,230,726 shares in total.
The allotment ratio is rounded 93.66% per accepting shareholder who has accepted the buyback offer of 4basebio AG in accordance with Section 2.2 a) either (i) at a shareholder purchase price (Aktionärskaufpreis) equal to or below the final purchase price (Endgültiger Kaufpreis) or (ii) at the final purchase price. For shareholders who have given an instruction to tender up to 100 shares, the allocation quota is 100%. As announced by the Company on 14 February 2020, the final purchase price of EUR 1.85 has been determined pursuant to Section 2.2 b) i) of the offer document at the end of the acceptance period.
About 4basebio AG: www.4basebio.com
4basebio AG, formerly operating under the name of Expedeon AG, is an enabler of exciting advances in medical science and patient care. After divestment of its immunology and proteomics products portfolio on January 1 2020, the Company changed its name to 4basebio AG reflecting the enhanced focus on technologies and products centered around DNA. The Company will focus on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines. Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.
4basebio AG has offices in Germany, Spain, UK, and the US. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).
For further information, please contact:
4basebio AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@4basebio.com
Investors’ information: investors.4basebio.com
MC Services AG (Investor Relations and International Media Relations)
Julia Hofmann
Phone: +49 89 210228 0
Email: 4basebio@mc-services.eu
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###
